PAT Rs 201.56 Crore | Granules India Q4 FY26 Results

Granules India announced its Q4 FY26 financial results on April 29, 2026, posting PAT of Rs 201.56 crore, a 32.57 percent year-on-year increase, as the Pharmaceuticals and API Manufacturing company delivered its January to March 2026 quarter earnings. Granules India Q4 FY26 results are closely tracked by investors as a key indicator of the company’s performance trajectory. This article covers the Granules India Q4 FY26 financial highlights, performance analysis, full year FY26 summary, management outlook, and frequently asked questions on Granules India Q4 results.

Granules India Q4 FY26 Financial Highlights

Granules India reported Q4 FY26 consolidated PAT of Rs 201.56 crore, a 32.57 percent year-on-year increase from Rs 152.03 crore in Q4 FY25. Revenue from operations grew 22.81 percent YoY to Rs 1,470.60 crore, driven by strong US generics demand and expanded pharmaceutical formulations and API volumes.

Metric	Q4 FY26	Q4 FY25	YoY Change
Revenue / Total Income	Rs 1,470.60 crore	Refer NSE/BSE filing	Grew 22.81 percent YoY
PAT	Rs 201.56 crore	Refer NSE/BSE filing	Higher 32.57 percent YoY
Full Year FY26 PAT	Refer annual filing	Refer filing	As reported
Dividend (FY26)	Not declared	Refer filing	FY26 final

Also Read: Bhansali Engineering Polymers Q4 FY26 Results

Granules India Q4 FY26 Performance Analysis

Granules India Q4 FY26 US generics business delivered strong volume and realisation trends as the company gained market share in its core molecules including paracetamol, ibuprofen, and metformin in regulated markets. Manufacturing capacity investments in FY24 and FY25 drove volume benefits in Granules India Q4 FY26.

Granules India Q4 FY26 EBITDA margin improvement reflected better product mix, improved US generics pricing, and operational leverage from higher capacity utilisation at its Gagillapur and Genome Valley API and formulation facilities.

Granules India Full Year FY26 Business Summary

FY26 was a strong recovery year for Granules India as the US generics market pricing environment stabilised after the inventory destocking pressure of FY25. The company progressed its innovator partnering strategy and CDMO pipeline for high-value molecules.

Granules India Q4 FY26 Outlook and FY27 Priorities

Granules India FY27 focus is on sustaining US generics revenue growth, filing new ANDAs in complex formulations, scaling the CDMO business for innovative pharmaceutical companies, and maintaining EBITDA margins above 20 percent.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!

Conclusion

The Granules India Q4 FY26 results provide investors with the company’s January to March 2026 performance data. Granules India Q4 FY26 PAT of Rs 201.56 crore reflects the operational performance in the Pharmaceuticals and API Manufacturing sector. Investors tracking Granules India Q4 results should review the complete audited financials on NSE and BSE exchange filings before making any investment decision. Granules India Q4 FY26 is an important milestone in the company’s annual earnings calendar.

This article on Granules India Q4 FY26 results is for informational and educational purposes only. It is not investment advice. Please consult a SEBI registered investment advisor before making any investment decision. Past performance is not indicative of future results.

Frequently Asked Questions on Granules India Q4 FY26 Results

What were the Granules India Q4 FY26 results?

Granules India Q4 FY26 results were announced on April 29, 2026. The company reported PAT of Rs 201.56 crore for the January to March 2026 quarter. Granules India Q4 FY26 details are in the official NSE and BSE exchange filings.

What was Granules India Q4 FY26 PAT?

Granules India Q4 FY26 PAT was Rs 201.56 crore, higher 32.57 percent YoY. The Granules India Q4 FY26 results were announced on April 29, 2026, at the board of directors meeting to approve audited financials.

What was Granules India Q4 FY26 revenue?

Granules India Q4 FY26 revenue was Rs 1,470.60 crore. Investors should refer to the NSE and BSE exchange filing for the full audited Granules India Q4 FY26 revenue breakdown and segmental performance data.

Did Granules India declare a dividend after Q4 FY26 results?

Granules India did not declare a dividend in the Q4 FY26 results announcement. Refer to the official exchange filing for confirmation.

What is the outlook for Granules India after Q4 FY26?

Granules India FY27 focus is on sustaining US generics revenue growth, filing new ANDAs in complex formulations, scaling the CDMO business for innovative pharmaceutical companies, and maintaining EBITDA margins above 20 percent. Investors should monitor management commentary and quarterly filings for updated guidance on Granules India Q4 FY26 performance sustainability into FY27.

How did Granules India Q4 FY26 compare year on year?

Granules India Q4 FY26 PAT of Rs 201.56 crore was higher 32.57 percent YoY. The year-on-year comparison for Granules India Q4 FY26 versus Q4 FY25 is available in the official audited NSE and BSE exchange filings.

What sector does Granules India operate in?

Granules India operates in the Pharmaceuticals and API Manufacturing sector in India and is listed on NSE and BSE. Granules India Q4 FY26 results reflect the broader Pharmaceuticals and API Manufacturing sector trends for the January to March 2026 quarter. Contextualising Granules India Q4 performance within industry dynamics requires reviewing sector-level data alongside management commentary.

Is Granules India a good investment after Q4 FY26 results?

Whether Granules India is a good investment after the Granules India Q4 FY26 results depends on your individual financial goals, risk tolerance, and investment horizon. Granules India Q4 FY26 results provide one data point on the company’s trajectory. Always consult a SEBI registered financial advisor before making any investment decision.

Recent Article

Torrent Power Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Usha Martin Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Triveni Engineering and Industries Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Utkarsh Small Finance Bank Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Venus Pipes and Tubes Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook